Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120
June 09, 2022 07:00 ET | Exavir Therapeutics
Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
May 23, 2022 07:00 ET | Exavir Therapeutics
NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET | Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
Long-Acting Injectab
Long-Acting Injectable Cabotegravir Is Highly Effective for the Prevention of HIV Infection in Cisgender Men and Transgender Women Who Have Sex With Men
May 18, 2020 06:37 ET | HIV Prevention Trials Network (HPTN)
DURHAM, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- The HIV Prevention Trials Network (HPTN) announced today results from HPTN 083, a global randomized, controlled, double-blind study that compared the...